MolecuLight Featured in Vizient Tech Watch as Key Technology to Visualize Bacterial Burden and Help Reduce Surgical Site Infections

Article is a follow-up to MolecuLight receiving an innovative technology contract from Vizient last year

pittsburgh, December June 2022 /PRNewswire/ – MolecuLight Corp., Leader in Point-of-Care Fluorescent Imaging for Detection of Wounds Containing Elevated Bacterial Burden technology watch Published as a key technique to visualize bacterial load and its location and help reduce surgical site infections. This article, “Fluorescent Imaging: New Technique Enables Instant Surgical Wound Bacterial Assessment” Appearing in Vizient’s technology watch (Medical Devices) Volume 3, released last week.

This technology watch Article Describes How Surgical Site Infection (SSI) Occurs in Up to 38% of Surgeries¹ (depending on anatomical location and type of surgery) and accounts for 20% of all healthcare-acquired infections². SSI was also the costliest of these infections, prolonging hospital stay by an average of 9.7 days and costing more than $20,000 per admitted patient^3,4.

Early and accurate diagnosis of postoperative bacterial load and infection is critical for prompt treatment before infection worsens. Some cases require laboratory testing to accurately diagnose the bacteria that colonize the wound, which can lead to the growth and spread of harmful bacteria and delay effective treatment. Test results can take days to weeks to become available, and if positive, it may be too late to prevent infection.

Clinicians need real-time diagnostic tools that they can use at the point of care to help provide immediate information on wound status and possible growth in bacterial burden. According to the article, MolecuLight imaging helps remove unnecessary subjectivity when assessing a wound for the presence of harmful bacteria by allowing rapid and accurate visualization of the location of elevated bacterial load in the wound, as well as clinical signs and symptoms. As such, it provides “valuable real-time information to inform clinical decision-making.”

Every recent review study⁵ Supporting this position, demonstrating the benefits of using MolecuLight to help clinicians visualize the bacterial burden of surgical site wounds:

• Seventy-six percent of surgical sites in the study that reached referral to a wound specialist had a clinically significant bacterial load (10⁴ until 10⁹ CFU/g), but Only 6.8% showed symptoms of infection, leading to delays in infection management.
• Point-of-care fluorescence imaging (using MolecuLight A generation:x equipment) for detection of high bacterial load 5.7 times higher sensitivity Compared to clinical signs and symptoms alone.
• Clinician experience with fluorescence imaging and interpretation (>200 imaging sessions) Increases the sensitivity of fluorescence imaging by a factor of 11.3 Compared with pure clinical signs and symptoms, the accuracy rate is 2.6 times higher.

“Clinicians need an objective way to detect infection or other surgical wound complications without relying on subjective judgment,” said Kelly Sandy-HodgersPh.D., founder and first chair of the International Surgical Wound Complications Advisory Panel (ISWCAP).

“Fluorescence imaging using MolecuLight has the potential to change the contemporary paradigm of postoperative wound management as it enables rapid and reliable detection of bacterial load and visualization of contamination at the point of care”.

In addition to Vizent’s profile technology watchLast year’s MolecuLight A generation:X® Fluorescent Wound Imaging Device Received innovative technology contracts From Vizient, Inc., the largest member-driven healthcare performance improvement company in the United States. MolecuLight’s new innovative technology contract A generation:x Demonstrating to Vizient members that the unique qualities of this device may improve the healthcare industry.

“We have been working with MolecuLight since 2021, when Vizient recognized the company as an award-winning supplier through our innovative technology program,” said Tammy MaurerVice President, Contracts and Project Services, Vizient, Inc. “After careful evaluation and selection by our board of clinical and supply chain professionals, Vizient’s innovative technology program recognizes innovative advances in care that enable healthcare providers to deliver the highest quality care while encouraging manufacturers to continue to pioneer new solutions.”

molecular light A generation:x and DX is the only imaging device for real-time detection of elevated wound bacterial load that is FDA cleared and CE and Health Canada approved. With clinical evidence including more than 60 peer-reviewed publications involving 1,500 patients, they are used by leading wound care institutions worldwide.

About MolecuLight Corp.

Molecular Light is the US subsidiary of MolecuLight Inc., a privately held medical imaging company that has developed and commercialized its proprietary fluorescence imaging platform technology in multiple clinical markets. MolecuLight’s commercial equipment kit, which includes the MolecuLight A generation:X® and DX™ Fluorescence Imaging System and its accessories are instant handheld imaging devices for instant detection and localization of wound bacterial load as well as digital wound measurement. The MolecuLight program is in U.S. Benefit from available reimbursement pathways that include two CPT® codes for physician work performed”Fluorescence imaging of bacteria presence, location and load” and facility payments hHospital Ohclinic Dingapartment(HOPD) and Onewalk around smallurgent CEnter(Ascending control) through a setting Onewalk around PPayment CClassification(armored personnel carrier) Task. The company is also commercializing its unique fluorescence imaging platform technology to address other global markets with unmet needs related to food safety, consumer cosmetics and other major industrial markets.

picture:

source molecular light